ABCL AbCellera Biologics Inc. - Fundamental Analysis

BEARISH

ABCL Stock | Fundamental Analysis & Investment Insights

NASDAQ • Healthcare • Biotechnology

Current Price Live

$3.04

Analyst Target

$9.83

+223.5% Upside

52W High

$6.51

52W Low

$1.89

Overview AI Snowflake Price Valuation More metrics Peers Insiders

At a glance

Key valuation, profitability, growth, and risk metrics.

Unlock key metrics

Market cap, P/E, ROE, margins, leverage and more.

AI Analysis

Confidence Score

85%

Analysis Accuracy

ABCL's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite strong revenue growth (37.6% YoY), the company reports a 0.00% profit margin, negative operating margin (-851.79%), and persistent losses, undermining long-term sustainability. The stock trades at a premium valuation (Price/Sales: 25.76) with no earnings or cash flow support, and its 5-year price decline of 92.5% reflects deep investor skepticism. Analysts' 'strong_buy' consensus appears disconnected from fundamental reality, suggesting speculative positioning.

Key Strengths

Strong revenue growth of 37.6% YoY indicates market traction and potential commercial scalability

High insider sentiment (60/100) suggests internal confidence despite lack of recent trades

Favorable balance sheet with low debt/equity (0.15) and high liquidity (Current Ratio: 10.10)

Significant 52-week price range ($1.89–$6.51) implies potential for upside if catalysts emerge

Analyst consensus remains 'strong_buy' with a high target price of $9.83, indicating potential upside if fundamentals improve

Key Risks

Piotroski F-Score of 1/9 signals severe financial deterioration and operational instability

Negative operating margin (-851.79%) and zero profit margin indicate unsustainable business model

No positive free cash flow or operating cash flow data, raising liquidity concerns

Stock has declined 92.5% over 5 years, reflecting persistent investor skepticism and poor capital efficiency

Absence of Altman Z-Score and Graham Number prevents reliable distress or fair value assessment, increasing uncertainty

Performance Snowflake

Multi-dimensional AI analysis across 5 key categories

Unlock AI-Powered Analysis

See Value, Future Performance, Past Performance, Financial Health & Dividend scores

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Unlock Price Charts

View historical price trends and analyst targets

Historical Performance Trends

Long-term financial metrics and growth patterns

Unlock Historical Data

View 3-year revenue, profit margins, and growth trends

Valuation Metrics

Key valuation ratios and pricing indicators

P/E, P/B, P/S, EV/EBITDA and more

Profitability, Growth & Financial Health

Detailed profit margins, ROE, debt ratios, and liquidity metrics

Unlock Detailed Metrics

View ROE, Operating Margin, Debt/Equity, Current Ratio and more

Sector Comparison & Peer Analysis

Compare ABCL against industry averages and similar companies

Unlock Sector Insights

See how ABCL compares to competitors and industry standards

Insider Trading & Analyst Ratings

Track insider transactions and Wall Street analyst recommendations

Unlock Insider Data

See recent insider buys/sells and analyst price targets

Past News Coverage

Recent headlines mentioning ABCL from our newsroom.

Newest → oldest

Back to All Stocks

TradingGPT V1 Copilot

Fundamentals • Valuation • Risk

Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends